ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH).
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeImmune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many cancers but are associated with immune-related adverse events (irAEs), including gastrointestinal toxicities such as colitis and hepatitis. This study aimed to evaluate the incidence of GI-irAEs, identify risk factors for their development, and assess the relationship between GI-irAEs, immunosuppressive treatment, and overall survival (OS) in a large real-world cohort.
methodsA multi-centre retrospective study was conducted across 12 National Health Service centres in the United Kingdom between June 2016 and 2018. Consecutive adult patients receiving ICIs for malignant melanoma, non-small cell lung cancer, or renal cell carcinoma were included. Clinically significant (≥ grade 2) GI-irAEs were recorded. Logistic regression was used to identify predictive factors for GI-irAEs and immunosuppressant (IS) use. OS was assessed using Kaplan-Meier survival analysis and log-rank testing.
resultsA total of 2,049 patients were included, of whom 1,649 were included in the GI-irAE subgroup analysis. Colitis occurred in 191 (9.3%) patients and hepatitis in 142 (6.9%). The majority of patients were treated with steroids alone; 22.3% of colitis cases and 15.8% of hepatitis cases required second line IS. Colitis and hepatitis were both associated with improved OS compared to patients without irAEs (p < 0.0001). Pre-existing autoimmune disease and combination immunotherapy predicted IS use in colitis, while grade 2-3 hepatitis predicted IS use. IS did not significantly affect OS in colitis but was associated with improved OS in hepatitis.
conclusionColitis and hepatitis are common GI-irAEs following ICI therapy and are associated with improved OS. The use of IS does not negatively impact survival, supporting their continued use in the management of steroid-refractory GI-irAEs and informing supportive care strategies for risk stratification and optimisation of toxicity management in patients receiving immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.